Search Results
Found 1 results
510(k) Data Aggregation
(95 days)
POWDER FREE LATEX EXAMINATION GLOVES (18 ML), BLUE TESTED FOR USE WITH CHEMOTHERAPY DRUGS
This glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.
Powder Free Latex Examination Gloves, Tested For Use With Chemotherapy Drugs (Blue).
This document is a 510(k) premarket notification approval letter for "Powder Free Latex Examination Gloves, Tested For Use with Chemotherapy Drugs (Blue)". It is not a study that proves the device meets acceptance criteria in the sense of a clinical trial or AI algorithm validation. Instead, it demonstrates substantial equivalence to a predicate device, which includes fulfilling certain performance standards for medical gloves.
Here's an analysis based on the provided document, addressing the requested points where information is available:
1. A table of acceptance criteria and the reported device performance
The document focuses on the chemotherapy drug permeation aspect of the gloves. While it doesn't explicitly state "acceptance criteria" in a separate column, the values presented are the "Average Breakthrough Detection Time in Minutes" for various chemotherapy drugs, which would be compared against a standard or established threshold for acceptable performance. The implicit acceptance criterion is that the breakthrough time should be as long as possible, ideally exceeding the duration of typical exposure.
Chemotherapy Drug | Reported Device Performance (Average Breakthrough Detection Time in Minutes) | Implicit Acceptance Criteria (based on general medical glove guidelines for chemotherapy) |
---|---|---|
Thiotepa (10.0 mg / ml) | 7.71 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Carmustine (BCNU) (3.3 mg / ml) | 63.03 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Dacarbazine (DTIC) (10.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Cyclophosphamide (Cytoxan) (20.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Doxorubicin Hydrochloride (2.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Fluorouracil (50.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Cisplatin (1.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Etoposide (Toposar) (20.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Paclitaxel (Taxol) (6.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Ifosfamide (50.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Methotrexate (25.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Mitomycin C (0.5 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Mitoxantrone (2.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Vincristine Sulfate (1.0 mg / ml) | > 240 | As high as possible, typically > 30 minutes for limited exposure, > 240 for extended. |
Note: The document explicitly states: "Please note that Thiotepa has an extremely low permeation time of less than 30 minutes." This indicates that for Thiotepa, the performance is below a generally accepted threshold for robust protection and needs careful consideration.
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
This information is not provided in the document. The document is an FDA approval letter, not a detailed study report. The results presented in the table are likely summarized from testing conducted by the manufacturer, but the specifics of the sample size (n
for each test) and provenance are not included.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
This is not applicable and not provided. This document pertains to the physical performance of a medical device (gloves) against chemical permeation, not a diagnostic or AI-driven system requiring expert interpretation or ground truth establishment in the traditional sense. The "ground truth" here is the objective measurement of chemical breakthrough.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
This is not applicable and not provided. Adjudication methods are typically used in studies involving human interpretation or subjective assessments, which is not the case for chemical permeation testing of gloves.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This is not applicable. This document is for a medical glove, not an AI-assisted diagnostic tool.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
This is not applicable. This document is for a medical glove, not an algorithm.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
The "ground truth" for the chemotherapy drug permeation data would be the objective measurement of the breakthrough time of the specific chemotherapy drugs through the glove material. This is determined by standardized chemical testing protocols (e.g., ASTM D6978 for medical gloves). It does not involve expert consensus, pathology, or outcomes data in this context.
8. The sample size for the training set
This is not applicable and not provided. This is not an AI/machine learning device that requires a training set. The "training" for such a device would be the manufacturing process itself, aiming to meet established performance standards.
9. How the ground truth for the training set was established
This is not applicable and not provided. As explained above, this is not an AI/machine learning device.
Ask a specific question about this device
Page 1 of 1